Cargando…

Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide

Detalles Bibliográficos
Autores principales:	Negoro, Eiju, Radivoyevitch, Tomas, Polprasert, Chantana, Adema, Vera, Hosono, Naoko, Makishima, Hideki, Przychodzen, Bartlomiej, Hirsch, Cassandra, Clemente, Michael J., Nazha, Aziz, Santini, Valeria, McGraw, Kathy L., List, Alan F., Sole, Francesc, Sekeres, Mikkael A., Maciejewski, Jaroslaw P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5143200/ https://www.ncbi.nlm.nih.gov/pubmed/27560106 http://dx.doi.org/10.1038/leu.2016.228

Ejemplares similares

Molecular features of early onset adult myelodysplastic syndrome
por: Hirsch, Cassandra M., et al.
Publicado: (2017)

Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML
por: Przychodzen, Bartlomiej, et al.
Publicado: (2017)

Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
por: Sugimoto, Yuka, et al.
Publicado: (2012)

Recurrent genetic defects on chromosome 5q in myeloid neoplasms
por: Hosono, Naoko, et al.
Publicado: (2016)

Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1
por: Saygin, Caner, et al.
Publicado: (2018)

The complexity of interpreting genomic data in patients with acute myeloid leukemia
por: Nazha, A, et al.
Publicado: (2016)

Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes
por: Nazha, A, et al.
Publicado: (2017)

Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes
por: Nagata, Yasunobu, et al.
Publicado: (2019)

Distinctive and common features of moderate aplastic anaemia
por: Patel, Bhumika J., et al.
Publicado: (2020)

Rational management approach to pure red cell aplasia
por: Balasubramanian, Suresh Kumar, et al.
Publicado: (2018)

Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms
por: Visconte, Valeria, et al.
Publicado: (2016)

Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia
por: Guan, Yihong, et al.
Publicado: (2020)

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
por: Sekeres, Mikkael A., et al.
Publicado: (2018)

Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q
por: Adema, Vera, et al.
Publicado: (2022)

Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development
por: Vishwakarma, Bandana A., et al.
Publicado: (2015)

Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors
por: McGraw, Kathy L., et al.
Publicado: (2014)

Immune dysregulation in extranodal NK/T cell lymphomas: potential roles in pathogenesis and immunotherapy
por: Polprasert, Chantana, et al.
Publicado: (2021)

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
por: Nishi, Rie, et al.
Publicado: (2020)

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

CLINICAL AND BIOLOGICAL IMPLICATIONS OF ANCESTRAL AND NON-ANCESTRAL IDH1 AND IDH2 MUTATIONS IN MYELOID NEOPLASMS
por: Molenaar, Remco J., et al.
Publicado: (2015)

Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes
por: Hattakitpanitchakul, Saroj, et al.
Publicado: (2021)

Under COVID of the night
por: Sekeres, Mikkael A.
Publicado: (2020)

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
por: Fenaux, Pierre, et al.
Publicado: (2017)

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
por: Sekeres, M A, et al.
Publicado: (2014)

Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes
por: Cluzeau, Thomas, et al.
Publicado: (2017)

Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin
por: Wang, Chen, et al.
Publicado: (2021)

A Randomized Multicenter Trial Comparing Low-Dose Prednisolone Versus Observation for Prevention of Recurrences in Adult Immune Thrombocytopenia
por: Pirunsarn, Arunrat, et al.
Publicado: (2018)

Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients
por: Amnuay, Kamalas, et al.
Publicado: (2019)

Detection of Red Blood Cell Membrane Proteins in Myelodysplastic Syndromes Using Eosin-5-Maleimide (EMA) Staining by Flow Cytometry
por: Uman, Navavee, et al.
Publicado: (2022)

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
por: List, A F, et al.
Publicado: (2014)

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes
por: McGraw, Kathy L., et al.
Publicado: (2015)

Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
por: List, A F, et al.
Publicado: (2015)

Complex Landscape of Alternative Splicing in Myeloid Neoplasms
por: Hershberger, Courtney E., et al.
Publicado: (2020)

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
por: Raza, Azra, et al.
Publicado: (2012)

Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine
por: Visconte, Valeria, et al.
Publicado: (2015)

Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence
por: Nazha, Aziz, et al.
Publicado: (2019)

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
por: Duong, Hien K, et al.
Publicado: (2009)

PRPF8 Defects Cause Missplicing in Myeloid Malignancies
por: Kurtovic-Kozaric, Amina, et al.
Publicado: (2014)

Naïve T-cells in Myelodysplastic Syndrome Display Intrinsic Human Telomerase Reverse Transcriptase (hTERT) Deficiency
por: Yang, Lili, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_jh2pfra8lur0lgaeev0e4u11jl